Instrument NameVertex PharmaceuticInstrument Symbol(VRTX-Q)

Instrument ExchangeNASDAQ

Many investors have a type of acrophobia (the fear of heights). It's not that they're worried about standing at the top of a ladder. Instead, their concern is focused on putting money in stocks when the market is skyrocketing.

Biotechs often need several years to realize their visions, even after they have a drug approved for the first time. There's typically plenty of upside in store for enterprising and patient investors.

Regulators are reviewing what could become a multi-billion-dollar drug.

Both stocks have made significant breakthroughs.

This biotech penny stock could more than triple, based on consensus forecasts.

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +1.23%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.32%. Stocks rallied on Tuesday, supported by some positive corporate news. Chip stocks rose, led...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.95%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.08%. Stocks are climbing today, supported by some positive corporate news. Chip stocks are moving...

From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know where to look.

The sky's the limit for these stocks.

VRTX earnings call for the period ending September 30, 2024.

It won't be able to be profitable without hitting its targets for both of these figures.

Monday U.S. Economic Lookahead Factory orders (Sept.) Featured Earnings Vertex Pharmaceuticals ...

These 12 innovative companies could deliver exponential returns over the next quarter century.

This stock might not be available for under $500 for long.

Its latest report of clinical data suggests it has a winner on its hands.

Is fear of missing out (FOMO) controlling your portfolio?

There's no need to change a winning formula.

This Nuvation Bio board member and longtime biotech industry insider carried out his first purchase since his appointment in January.

These profitable companies are facing long-term growth runways.

These stocks look like slam-dunk picks for growth investors.

These longtime leading biotech stocks still have plenty of upside ahead.

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

These companies have plenty of growth runway left.

/CNW/ - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for...

/CNW/ - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for PrCASGEVY® (exagamglogene...